Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia  + (NI)
• Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia  + (NI)
• Inglis et al. (2020): Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT  + (NI)
• Inglis et al. (2020): Effects of High-Dose Vitamin D Supplementation on Phase Angle and Physical Function in Patients with Prostate Cancer on ADT  + (NI)
• Antunac et al. (2018): Vitamin D Supplementation and Survival in Metastatic Colorectal Cancer  + (NI)
• Antunac et al. (2018): Vitamin D Supplementation and Survival in Metastatic Colorectal Cancer  + (NI)
• Lissoni et al. (2009): A Randomized Study of Chemotherapy versus Biochemotherapy with Chemotherapy plus Aloe arborescens in Patients with Metastatic Cancer  + (NI)
• Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy  + (NI)
• Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer  + (NI)
• Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer  + (NI)
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (NI)
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (NI)
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (NI)
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (NI)
• Sanaati et al. (2016): Effect of Ginger and Chamomile on Nausea and Vomiting Caused by Chemotherapy in Iranian Women with Breast Cancer  + (NI)
• Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial  + (NI)
• Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators  + (NI)
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (NI)
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (NI)
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (NI)
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (NI)
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (NI)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (No data available)
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (No difference between arms)
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (No difference between arms)
• Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial  + (No difference between arms (p=0.4270), even after controlling for tumor site, treatment method and cancer stage at week 7 or the entire study period)

• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (No difference between arms.)
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (No difference between arms.)
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (No difference between arms.)

• Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial  + (No difference between groups in postoperative fatigue scores (p's>0.05))
• Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial  + (No difference between selenium arm (26.92±6.26 days) and placebo arm (25.81±4.33 days); p=0.38)
• Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial  + (No difference between the 2 arms, p = .68)
• Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy  + (No difference between the arms.)
• Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy  + (No difference between the arms. Significa … No difference between the arms. </br>Significantly better sleep within the guarana arm compared to baseline.</br>Better sleep quality after the use of guarana only in the day 49 comparison and in guarana-placebo arm of the intragroup analysis</br>Intergroup comparison of guarana and placebo: </br>Day 21: p = .19</br>Day 49: p .05nd placebo: Day 21: p = .19 Day 49: p .05)
• Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial  + (No difference between the arms; p= 0.69)
• Hoopfer et al. (2015): Three-arm randomized phase III trial: Quality aloe and placebo cream versus powder as skin treatment during breast cancer radiation therapy  + (No difference between the treatment arms was found among the arms in the Likert scales measuring the change in the symptoms comparedwith the previous week.)
• Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial  + (No differences between the groups during irradiation (boswellia: 0-84mg/week; placebo: 0-112mg/week))
• Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme  + (No radiation-related headaches and ulcerat … No radiation-related headaches and ulcerations occurred in either arm; vomiting symptoms and oedema only occurred in the control-arm; all other symptoms occurred in both arms, but less frequently and less intensively in the enzyme-arm than in the control-arm.</br></br>Deterioration of the general status in 5.5% of the enzyme-arm and in 11.4% of the control-arm, no changes of the general status in 94.5% of the enzyme-arm and 88.6% of the control-arm.e enzyme-arm and 88.6% of the control-arm.)
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. difference between the arms (reflexology arm/control arm: ß= -0.335 [3.81]; p=0.38, reflexology arm/foot massage: NI).)
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. differences between the arms (reflexology arm/control arm: 0.387 [2.194]; p= 0.86, reflexology arm/control arm: NI))
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. differences between the arms (reflexology arm/control arm: ß= -0.487 [1.21]; p=0.69; reflexology arm/foot massage arm: NI))
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. differences between the arms (reflexology arm/control arm: ß= -2.87 [0.389]; p=0.46; reflexology arm/foot massage arm: NI))
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. differences between the arms (reflexology arm/control arm: ß= -2.87 [0.389]; p=0.46; reflexology arm/foot massage arm: NI))
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. differences between the arms (reflexology arm/control arm: β=0.212[0.124], p=0.089, reflexology arm/foot massage arm: NI))
• Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer  + (No sig. differences between the arms (reflexology arm/control arm: ß= -0.886 [1.259]; p=0.48; reflexology arm/foot massage arm: NI))
• Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment  + (No sig. differences between the arms (β= 0.195 [0.67]; p=0.77))
• Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment  + (No sig. differences between the arms (β= 0.599 [0.36]; p=0.10))
• Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment  + (No sig. differences between the arms (β= 1.659 [0.88]; p=0.06))
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (No sign. difference between arms (p=NI))
• Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation  + (No sign. differences according to grade (no values given, only graph and p-values): grade 1: p = 0.31, grade 2: p = 0.25, grade: 3: p = 0.93, grade 4: p = 0.32 Mean length: no significant difference seperated by diagnosis (ALL, CML, AML).)
• Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin  + (No significant arm difference (p=0.414-0.959))
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (No significant arm differences after 7 weeks (p=0.9328).)
• Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2)  + (No significant arm differences in the mean … No significant arm differences in the mean PSA doubling time (intervention arm 21 months vs. control arm 15 months; p=0.446, not significant)</br></br>Post hoc analysis: after adjustment for key demographic variables and PSA levels possibly reduced by weight loss and associated altered hemoconcentration measurement: slowed PSA doubling in intervention arm compared to control arm; however, questionableared to control arm; however, questionable)